Our fields

One Health paradigm promotes a global effort to achieve the best solutions for human and animal health considering the environment.

Human health

Human Health

Tacle infectious
diseases

Animal health

Animal Health

Reduce use
of antibiotics

Microbes and environment

Microbes &
Environment

Control microbes
proliferation /
dissemination

Nutraceuticals

Nutraceuticals

Role of gut
microbiota

Challenges in
infectious diseases

Each year, infectious diseases triggered by bacteria, parasites, viruses and fungi are responsible for 5.7 million deaths worldwide. Infectious diseases remain the leading cause of death in several countries, increasingly as a result of antibiotic resistance. Antimicrobial resistance, driven by misuse of antimicrobials in people and in animals, has become a serious public health threat for effective treatment of an ever-increasing range of infections. Resistant pathogens are causing 700,000 deaths per year, and 10 million deaths per year are expected by 2050, a number higher than the 8.2 million caused by cancer today. The medical need for improved therapeutic solutions for infectious diseases is striking.

Challenges in infectious diseases.
Vibiosphen vision

Vibiosphen vision

Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than 6 years of expertise, offers support for the design of preclinical studies for the development of innovative solutions in the fight against infectious diseases.

Team and scientific board

Maxime Fontanié

Founder and CEO

Maxime is an entrepreneur with a degree in engineering and an executive MBA. He has a broad expertise in pharmaceutical R&D, biotechnologie, strategy and business development.. Maxime Began his career at INSERM (french academic institute). In 2002, he moved to Sanofi where he conducted number of drug development as team leader, international Projet Manager, and pharmacologist Scientist. Maxime cofunded Vibiosphen in 2014 and Enterosys in 2017.

Dr Patricia Martin

CSO

Dr. Patricia Martin has a solid background in molecular microbiology in the context of the pathophysiology of infectious diseases.
After a thesis on the genomic instability of an antibiotic-producing bacterium, she turned to study the pathogenicity of bacteria, such as meningococcus in Oxford then in Paris and Escherichia coli in Toulouse. During this academic career she acquired skills in project management, team management and communication.
In 2020 she joined VibioSphen as Chief Scientific Officer.
Patricia Martin is the author of 34 international publications, 2 patents and is authorized to supervise research.

Christophe Fremez

Pharmacologist Scientist

After an experience at INSERM and Sanofi, Christophe joined the company in January 2015 as pharmacologist scientist.  He has a master degree in infectious immunology field. With a strong experience in in vivo mouse model, molecular biology, microbiology and immunology , Christophe is responsible for the design and the achievement of preclinical infectious experiments (pulmonary infection, UTI, …) in bsl2 and Bsl3 facilities. He is in charge of quality management.

Alexandre Laurent

Pharmacologist Scientist

Alexandre is project manager for the in vitro tests. After validating his master degree in biology engineering in 2020, he was recruited by Vibiosphen as Pharmacologist scientist. Alexendre has specific skills in cell culture, immunology and microbiolgy. As assitant lab manager, he is responsible for material and devices.

Julie Vignau

PhD student

After graduating from a Master in Drug Sciences, specializing in Biotherapies and Advanced Medicinal Products, from the University of Nantes, Julie Vignau joined VibioSphen as a PhD Student in 2021.
She has experience in both academic laboratories, in Nantes and in Liverpool, and in a biotechnology company, in the Netherlands.
She acquired skills in cell culture, immunology, cancerology, and inflammation. Indeed, she has worked on preclinical development of different type of biotherapeutics, such as vaccines, antibodies, or small molecules, targeting tumour cells, bacteria, and inflammatory diseases.

Dr. Christian Giske

Member of scientific committee

Dr. Christian Giske has multiple years of experience as senior consultant clinical microbiologist and associate professor at Karolinska University Hospital and Karolinska Institutet. The main focus of his research is pneumonia and antimicrobial resistance. He is responsible for several projects including multidrug- and extensive drug-resistance increases among clinically important bacterial species. Factors promoting the long-term carriage and invasive disease in strains of these species are also investigated. The group has built up expertise in the characterization and handling of various drug resistant strains from different continents.

Dr Mariette Ducatez

Member of scientific committee

Mariette Ducatez is research director at INRAe, in Interactions Hosts-pathogens (IHAP) research unit. She worked in Luxembourg and then in the United States before coming to Toulouse. She has been a researcher in virology since 2006 with a particular interest in influenza viruses with a human-animal interface, and more generally animal respiratory viruses. She works both on animal virus surveillance projects (mainly in Africa), projects aimed at understanding the pathogenesis and transmission of these pathogens, as well as on issues of prevention and control of viral diseases.

Laurent Fraisse

Member of scientific committee

Laurent Fraisse joined the Drugs for Neglected Diseases initative (DNDi) as Research & Development (R&D) Director and Executive Team member in October 2019. In this capacity he drives DNDi’s science strategy and oversees all research and clinical activities worldwide.
Laurent joined Sanofi in 1999 after a ten-year tenure as a science leader in Elf Atochem. During 20 years at Sanofi, he rose to serve as Vice President for Infectious Disease R&D, addressing medical needs in bacterial, parasitic, and viral related infections. He then joined Evotec as Executive Vice President for infectious diseases with the mission to accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives.

Dr Etienne Meunier

Member of scientific committee

Etienne Meunier CNRS Researcher has open his emerging research team “INFLAME” in 2017 at the IPBS institute. The unifying thematic of his research is the investigation of the immune and microbicidal functions of programmed necrosis upon microbial challenge. This research area has been matured along his post-doctoral experience in Switzerland (Biozentrum, Univ. of Basel) but also by the addition of numerous supports from collaborations, which could lead to important contribution releases in the identification of host cell components that modulate the activation of innate immune sensors. This research was strongly supported by fundings from various agencies, such as the ERC council (ERC StG), the ANR, the FRM young PI emerging program, the ATIP-Avenir program, the ESCMID society